Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has lodged an Appendix 3Y with the ASX following the US registration of securities in the name of Karen Agersborg, ensuring compliance with disclosure obligations. The company emphasizes that its current practices are in line with the ASX Listing Rules, demonstrating their commitment to transparency and adherence to regulatory standards. Clinuvel, a pioneer in photomedicine, continues to develop treatments for patients with acute and life-threatening disorders, with SCENESSE® as its leading approved photoprotective drug.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
